Patents by Inventor Waldemar Priebe

Waldemar Priebe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220347168
    Abstract: Provided is a method of treating cancer cells localized in the lung by administering to such patients a therapeutically effective amount of a liposomal annamycin formulation (L-Ann).
    Type: Application
    Filed: May 12, 2022
    Publication date: November 3, 2022
    Inventors: Waldemar PRIEBE, Rafal ZIELINSKI, Izabela FOKT, Stanislaw SKORA
  • Publication number: 20220175744
    Abstract: Provided herein are methods of treating patients with a combination of a transcription inhibitor (e.g., a STAT3 inhibitor) and an immune checkpoint blockade therapy (e.g., anti-PD-1 therapy, anti-PD-L1 therapy, anti-CTLA-4 therapy). The patient may have a proliferative disease, such as cancer or psoriasis. The patient may have a pathogenic infection.
    Type: Application
    Filed: April 2, 2020
    Publication date: June 9, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Waldemar PRIEBE, Rafal ZIELINSKI, Michael CURRAN, Midan AI
  • Publication number: 20220105115
    Abstract: Provided is a method of making a preliposomal Annamycin lyophilizate, the composition made by the method, and the use of the composition made thereby in the treatment of cancer.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 7, 2022
    Inventors: Donald PICKER, Waldemar PRIEBE
  • Publication number: 20220105116
    Abstract: Methods of reconstituting lyophilized Annamycin and methods of treating patients are described.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 7, 2022
    Inventors: Donald PICKER, Waldemar PRIEBE
  • Publication number: 20220023326
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Application
    Filed: June 4, 2021
    Publication date: January 27, 2022
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Patent number: 11026960
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 8, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Patent number: 10703721
    Abstract: In one aspect, the present disclosure provides caffeic acid derivatives of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure provides pharmaceutical compositions and methods of using of the compounds disclosed herein, including for the treatment of cancer.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: July 7, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Stanislaw Skora, Izabela Fokt, Rafal Zielinski, Arumugam Jayakumar, Radjendirane Venugopal
  • Publication number: 20190224225
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 25, 2019
    Inventors: Waldemar PRIEBE, Marcin CYBULSKI, Izabela FOKT, Stanislaw SKORA, Charles CONRAD, Timothy MADDEN
  • Patent number: 10358439
    Abstract: Provided herein are compounds which intercalate into the DNA of a cell and are capable of crossing the blood brain barrier of a formula provided herein. Pharmaceutical compositions of the compounds and methods of treating cancer, for example brain, lung, or pancreatic cancer, are also provided herein.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: July 23, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Liwei Guo, Arkadiusz Kazimierski, Izabela Fokt, Charles Conrad, Timothy Madden
  • Publication number: 20190177276
    Abstract: In one aspect, the present disclosure provides caffeic acid derivatives of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure provides pharmaceutical compositions and methods of using of the compounds disclosed herein, including for the treatment of cancer.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 13, 2019
    Inventors: Waldemar PRIEBE, Stanislaw SKORA, Izabela FOKT, Rafal ZIELINSKI, Arumugam JAYAKUMAR, Radjendirane VENUGOPAL
  • Patent number: 10201554
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: February 12, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Publication number: 20180251454
    Abstract: Provided herein are compounds which intercalate into the DNA of a cell and are capable of crossing the blood brain barrier of a formula provided herein. Pharmaceutical compositions of the compounds and methods of treating cancer, for example brain, lung, or pancreatic cancer, are also provided herein.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 6, 2018
    Applicant: Board of Regents, The University of Texas System
    Inventors: Waldemar PRIEBE, Liwei GUO, Arkadiusz KAZIMIERSKI, Izabela FOKT, Charles CONRAD, Timothy MADDEN
  • Publication number: 20160184336
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Application
    Filed: April 4, 2014
    Publication date: June 30, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Patent number: 9096499
    Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: August 4, 2015
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Nicholas Donato, Moshe Talpaz, Slawomir Szymanski, Izabela Fokt, Alexander Levitzki
  • Patent number: 9000179
    Abstract: Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: April 7, 2015
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Stanislaw Skora, Timothy Madden, Izabela Fokt, Charles Conrad
  • Publication number: 20150094343
    Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.
    Type: Application
    Filed: June 4, 2014
    Publication date: April 2, 2015
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Waldemar PRIEBE, Izabela FOKT, Slawomir SZYMANSKI, Timothy MADDEN, Jeffrey MYERS, Charles CONRAD
  • Patent number: 8927506
    Abstract: Novel compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are provided herein.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: January 6, 2015
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Publication number: 20140329901
    Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.
    Type: Application
    Filed: January 3, 2014
    Publication date: November 6, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Waldemar PRIEBE, Nicholas DONATO, Moshe TALPAZ, Slawomir SZYMANSKI, Izabela FOKT, Alexander LEVITZKI
  • Publication number: 20140228414
    Abstract: Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.
    Type: Application
    Filed: December 11, 2013
    Publication date: August 14, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Waldemar PRIEBE, Stanislaw SKORA, Timothy MADDEN, Izabela FOKT, Charles CONRAD
  • Patent number: 8779151
    Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: July 15, 2014
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Waldemar Priebe, Izabela Fokt, Slawomir Szymanski, Timothy Madden, Jeffrey Myers, Charles Conrad